Skip to main content

NCT01855074 - Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antip

Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone


CSR Summary

Not Available


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Risperidone
Product Name
RISPERDAL CONSTA®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
80
% Female
40.5%
% White
N/A
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
RISSCH4186
Data Partner
Johnson & Johnson
Condition Studied
Schizophrenia
Mean/Median Age (Years)
43.0

Supporting Documentation

Clinical Study Report
Statistical Analysis Plan
Study Phase 
4
Additional Information: 

Please note: individual participant-level data are not available for this trial. Only the statistical analysis plan, and full clinical study report are available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.